… which has now established means by which to qualify biomarkers for use in drug development,
but there is a lack of validated biomarkers at this time (14–16). Commercial development …

… Patients eligible for inclusion in PrepareME needed to have existing or newly diagnosed
stage 5 chronic kidney disease (CKD… The CI and TMG decided to reconsider the name of the …

… Coma and apnoea occur in the final phases of an overdose … therapy and frequently reassess
appropriateness and safety. … state or provincial regulatory requirements before writing the …

… -stage organ failure, dialysis is used in the chronic treatment of >2 million people worldwide.
… interventions without the oversight and patient protections normally afforded in clinical trials. …

… We reviewed studies reporting on patients diagnosed with RCC that was metastatic at … at
least an intermediate risk, and did not enroll patients who were eligible for upfront surveillance …

… The demographics of the end-stage kidney disease (ESKD) … , large prospective trials focusing
on elderly patients are … considered based on metabolic requirements, volume status and …

… Eligible patients were between the ages of 18 and 75 years, had chronic kidney disease of
stage 3 … This factor may indicate the need to reconsider the threshold of iron measures below …

… characterise the potential eligibility of real-world patients for oncology clinical trials. We …
eligibility criteria from practice changing phase III clinical trials to a cohort of 379 registry patients …

… and heart failure and contributes to the progression of renal disease to end-stage renal disease
(ESRD)… These trials led to a rethinking of the ‘Hb target’ to aim at with ESA, and to a more …

… of preexisting/worsening renal dysfunction but should be used … in the early phase of myocardial
dysfunction with increased … dose requirements tend to increase over time in HF patients, …